Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – C-o-group doai
Patent
1994-09-12
1995-06-27
Chang, Ceila
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C-o-group doai
514866, A61K 31045
Patent
active
054280664
ABSTRACT:
A method of treating a cluster of diseases associated with elevated blood sugar levels comprising the administration of a dietary supplement of chiro-inositol. Chiro-inositol is an essential element for the synthesis of an insulin-directed mediator apparently responsible for the activation of pyruvate dehydrogenase-phosphatase. Disease conditions commonly associated with insulin-resistance, such as hypertension, lactic acidosis, obesity, coronary artery disease, and the like, are treated by administration of sufficient chiro-inositol to meet normal metabolic levels.
REFERENCES:
patent: 4446064 (1984-05-01), Larner
patent: 4735936 (1988-04-01), Siren
patent: 4797390 (1989-01-01), Siren
patent: 4801597 (1989-01-01), Stacpoole et al.
patent: 4839466 (1989-06-01), Saltiel
patent: 4906468 (1990-03-01), Saltiel
patent: 4927831 (1990-05-01), Malamas
patent: 5019566 (1991-05-01), Siren
patent: 5023248 (1991-06-01), Siren
patent: 5091596 (1992-02-01), Kennington et al.
patent: 5122603 (1992-06-01), Larner
patent: 5124360 (1992-06-01), Larner
patent: 5183764 (1993-02-01), Kennington
patent: 5217959 (1993-06-01), Sabin
patent: 5342832 (1994-08-01), Siren
Cecil "Textbook of Medicine" Saunders Co. p. 1059 (1983).
Price, et al., Effect of Aldose Reductase and Resistance to Ischemic Diabetes, Diabetes, 37(7), pp. 969-973, (Eng) 1988.
Knudsen, et al., Myo-inositol Normalizes Decreased Sodium Permeability of the Blood-brain Barrier in Streptozotocin Diabetes, Neuroscience (Oxford), 29(3), pp. 773-777, (Eng) 1989.
Hallman, et al., Inositol Supplementation in Respiratory Distress Syndrome: Relationship Between Serum Concentration, Renal Excretion and Lung Effluent Phospholipids, Pediatrics, vol. 110, No. 4, pp. 604-610, 1987.
Clements, New Therapies for Chronic Complications of Older Diabetes Patients, American Journal of Medicine, 80 (Supp ISA), pp. 54-60, 1986.
Holub, The Nutritional Significance, Metabolism and Function of Myo-inositol and Phosphatidylinosital in Health and Disease, Advanced Nutrition Research, vol. 4, pp. 107-141, 1982.
Windholz, The Merck Index, No. 4861, p. 722, 1983.
Hamster Diet Inositol as Part of Vitamin Mix, ICN Catalogue, p. AD-19, 1989.
Phillips, et al., Cyclitols in Soybean, J. Agric. Food Chem., 30(3) pp. 456-458, 1982.
Baumgartner, et al., Isolation and Identification of Cyclitols in Carob Pods, J. Agric. Food Chem., 34(5), pp. 827-829, 1986.
Williamson, et al., Diabetes-Induced Increases in Vascular Permeability and Changes in Granulation Tissue Levels of Sorbitol, Myo-inositol, Chiroinositol, and Scyllo-inositol are Prevented by Sorbinil, Metabolism, vol. 35, No. 4, Suppl. 1, pp. 41-45, Apr. 1986.
Narayanan, et al., Pinitol-A New Anti-Diabetic Compound From the Leaves of Bougainvillea-Spectabilis, Current Science, vol. 56, No. 3, pp. 139-141, (Feb. 5, 1987).
Clements, et al., Myoinositol Metabolism in Diabetes Mellitus, Diabetes, vol. 26, No. 3, pp. 215-221, 1977.
Larner, J. Cyclic Nucleotide Res. 8, 1982, pp. 289-296.
Niwa et al., J. Chromatography, 277, 1983, pp. 25-39.
Larner et al., Rec. Progress in Hormone Res. 38, 1982, pp. 511-556.
Cheng, et al., Diabetes, 29 1980, pp. 659-661.
Thompson, et al., Mol Cell. Biochem. 62, 1984, pp. 67-75.
Cheng, et al., J. Biol. Chem., 260(9), 1985, 5279-5285.
Messina, et al., Endocrinology 121, (4) 1987, pp. 1227-1232.
Malchoff, et al., Endocrinology, 102, (4), 1987, pp. 1327-1337.
Cheng, et al., Ann. Rev. Physiol., 47, 1985, pp. 405-424.
Suzuki, et al., J. Biol. Chem., 262(7), 1987, pp. 3199-3204.
Sato, et al., Arch. Biochem. Biophys. 260, 1988, pp. 377-387.
Greene, et al., J. Clin., Invest., 72, 1983 pp. 1058-1063.
Greene, et al., J. Clin. Invest. 55, 1975, pp. 1326-1336.
Clements, et al., Diabetes, 26(3), 1977, pp. 215-221.
Saltiel, et al., Proc. Natl. Acad. Sci. USA, 83, 1986 pp. 5793-5747.
Mato, et al., Biochem. Biophys. Res. Commun. 146(2), 1987, pp. 764-779.
Larner, et al., Biochem. Biophys. Res. Commun. 151(3), pp. 1416-1426 (1988).
Mato, et al., J. Biol. Chem., 262(5), 1987, pp. 2131-2137.
Romero, et al., Science, 240, 1988 pp. 504-511.
Kennington et al., J. Cell Biochem. Suppl. 0(13 part A), 1989 p. 142.
Sato, et al., Endocrinology, 123(3), 1988, pp. 1559-1564.
Huang, et al., FASEB, 1988, Abstract 1626.
Kennington, et al., Analytical Biochem. 181, 1989, pp. 1-5.
Huang Laura C.
Kennington Alison
Larner Joseph
Chang Ceila
McNichol, Jr. William J.
Sleath Janet
LandOfFree
Method of reducing elevated blood sugar in humans does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of reducing elevated blood sugar in humans, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of reducing elevated blood sugar in humans will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-287963